Sarepta’s Exondys Successor Bounces Back From Clinical Hold But All Eyes On Gene Therapy
Executive Summary
The firm’s exon-skipping Duchenne muscular dystrophy asset will resume clinical study in the US following the lifting of a clinical hold but observers seem more invested in the fate of its gene therapy candidate for the condition.
You may also be interested in...
Finance Watch: Third Harmonic Launches The Largest IPO In Months
Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.
Duchenne Breakthrough Hopes Rise With More Data From Sarepta Gene Therapy
More data from Sarepta’s mid-stage studies help bolster confidence in the gene therapy but will the US FDA call in the drug for an early appraisal or await Phase III data next year?
ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.